Michael S. Grimley, MD
- Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency
- Professor, UC Department of Pediatrics
- michael.grimley@cchmc.org
- Board Certified
About
Biography
I’ve been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.
Similarly, my exposure to pediatric and adult hematology/oncology patients and physicians in medical school confirmed that I wanted to work with these patients and colleagues.
As a bone marrow transplant physician, I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.
My research involves finding treatments for and prevention of viral infections in immunocompromised patients.
When I’m not treating patients or involved in research, I enjoy spending time with my family.
MD: Emory University School of Medicine, Atlanta, GA, 1992,
Residency: Wilford Hall Medical Center, Lackland AFB, TX, 1995,
Fellowship: Cincinnati Children’s Hospital Medical Center, 1999,
Certifications: General Pediatrics, Pediatric Hematology/Oncology; Licenses: Ohio, Texas
Interests
Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major. Blood advances. 2025; 9(24):6370-6379.
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction. Blood advances. 2025; 9(24):6305-6313.
Transcriptomic analysis uncovers hidden intronic and synonymous pathogenic variants in red cell membrane disorders. Blood. 2025; 146(Supplement 1):282-282.
Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease. Blood. 2025; 146(Supplement 1):2542-2542.
BK polyomavirus genotype IV isolates from virus-specific T-cell therapy recipients. Microbiology Resource Announcements. 2025; 14(10):e0062525.
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplantation and Cellular Therapy. 2025; 31(10):826.e1-826.e10.
Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2025; 60(8):1102-1107.
Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Nature Medicine. 2025; 31(7):2204-2212.
Receipt of Fluoroquinolone Prophylaxis is not Associated With Development of Vancomycin-Resistant Enterococcus Colonization During Pediatric Hematopoietic Cell Transplantation. Journal of the Pediatric Infectious Diseases Society. 2025; 14(3).
Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season. Journal of Infectious Diseases. 2025; 231(1):e123-e131.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey